Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CytomX Therapeutics
Biotech
BMS exits next-gen Yervoy pact, taking $300M in biobucks with it
Bristol Myers Squibb is walking away from CytomX's potential successor to Yervoy and wiping $300 million off the value of the alliance in the process.
Nick Paul Taylor
Mar 12, 2024 7:07am
Xencor pulls back from Genentech cancer pact to cut costs
Nov 8, 2023 6:00am
AbbVie sidelines CytomX after seeing midphase oncology ADC data
Mar 28, 2023 6:30am
Moderna caps off busy week with $1.2B CytomX collaboration
Jan 6, 2023 8:32am
Regeneron swoops in with $2B biobucks pact for troubled CytomX
Nov 17, 2022 9:40am
CytomX slashes headcount by 40% after breast cancer setback
Jul 14, 2022 8:22am
